ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP

GHENT, Belgium, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] announced that it will today present additional data from post-hoc analyses of the Phase II TITAN study of its wholly-owned Nanobody®, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (aTTP), at the first European Congress on Thrombosis and Haemostasis (ECTH), being held from 28-30 September 2016 in The Hague, The Netherlands. Shortly after the conference, the presentation will be available on the Ablynx website under the R&D portfolio section .

Acquired TTP is an acute, ultra-rare, life-threatening blood clotting disorder in which uncontrolled platelet aggregation and microclot formation cause small blood vessel occlusions throughout the body [1] , resulting in thrombotic complications and widespread organ damage [2] . Despite the current standard-of-care treatment of daily plasma exchange (PEX) and immunosuppression, episodes of aTTP are still associated with a mortality rate of up to 20%, with most deaths occurring within 30 days of diagnosis [3] . Furthermore, patients are at risk of acute thromboembolic complications (e.g. stroke, venous thrombosis and myocardial infarction) and of recurrence of disease. In addition, some patients are refractory to therapy [4] , which is associated with a very poor prognosis for survival of an acute episode of aTTP. Data from the French Reference Center for Thrombotic Microangiopathies showed that 50% of patients who died from an acute episode were refractory to treatment [5] .

Post-hoc analyses of the Phase II TITAN study data were performed to assess the impact of caplacizumab on a composite endpoint of major thromboembolic complications and aTTP-related mortality, as well as on refractoriness to standard treatment. The results demonstrate that a clinically meaningful lower proportion of subjects treated with caplacizumab experienced one or more major thromboembolic events, or died, as compared to placebo (11.4% versus 43.2%). In addition, fewer caplacizumab-treated patients, compared to those who received placebo, were refractory [6] to treatment (5.7% versus 21.6%; and 0% versus 10.8%, respectively depending on the definition of refractoriness 4 ). There were two deaths in the placebo group and both those patients were refractory to treatment; no deaths were reported in the caplacizumab group.

A Phase III confirmatory study of caplacizumab is currently ongoing which includes prospectively defined assessments of these clinically relevant endpoints.

Professor Flora Peyvandi, Principal Investigator for the TITAN study at IRCCS Maggiore Hospital Foundation, University of Milan, Italy, commented: "Acquired TTP is a very severe disease with high unmet medical need. Any new treatment option would need to act fast to immediately inhibit the formation of micro-clots in order to protect the patient during the acute phase of the disease and so have the potential to avoid the resulting complications. The topline results and the subsequent post-hoc analyses of the Phase II TITAN data demonstrate that caplacizumab has the potential to reduce the major morbidity and mortality associated with acquired TTP, and confirm our conviction that it should become an important pillar in the management of acquired TTP."

About caplacizumab

Caplacizumab is a highly potent and selective bivalent anti-von Willebrand Factor (vWF) Nanobody that received Orphan Drug Designation in the United States and Europe in 2009. Caplacizumab blocks the interaction of ultra-large vWF multimers (ULvWF) with platelets and, therefore, has an immediate effect on platelet aggregation and the ensuing formation and accumulation of the microclots that cause the severe thrombocytopenia and organ and tissue damage in aTTP. This immediate effect protects the patient from the manifestations of the disease while the underlying disease process resolves.

The efficacy and safety of caplacizumab in conjunction with the standard of care (PEX) were evaluated in the Phase II TITAN study in 75 patients with aTTP. Caplacizumab was well-tolerated and the primary endpoint of reduction in time to platelet normalisation was met (p=0.005). Treatment with caplacizumab resulted in a nearly 40% reduction in time to platelet count normalisation as compared to placebo (i.e., a faster reversion of thrombocytopenia with consequent reduced use of PEX). Moreover, during treatment, caplacizumab reduced aTTP recurrences by 71% compared to placebo when administered as an adjunct to standard of care [7] . 

These Phase II results will serve as the basis for filing for conditional approval of caplacizumab in Europe in early 2017. The confirmatory Phase III HERCULES study is currently ongoing and will support the BLA filing in the United States. Results from this Phase III study are expected by the end of 2017.

Caplacizumab has the potential to be the first therapeutic specifically approved for the treatment of acquired TTP.

About aTTP

aTTP is an acute, ultra-rare, life-threatening, blood clotting disorder, affecting up to 11 per million people worldwide. It has a sudden onset caused by impaired activity of the ADAMTS13 enzyme (typically <10% of that in normal plasma), leaving ULvWF molecules uncleaved (vWF is an important protein involved in the blood clotting process). These ULvWF molecules spontaneously bind to blood platelets, resulting in severe thrombocytopenia (very low platelet count) and micro-clot formation in small blood vessels throughout the body, leading to thrombotic complications and widespread organ damage.

Up to 20% of patients die from an initial aTTP episode with most deaths occurring within 30 days of diagnosis. In addition to the acute risks of the disease, patients experiencing an episode of aTTP may suffer long-term consequences such as cognitive deficits, depression, and arterial hypertension [8] , and are at risk for recurrence. The recurrence rate ranges from 10-84% [9] and typically occur within 1-2 years [10] , but recurrences have been reported up to 30 years after the initial episode [11] .

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies® , proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com .

For more information, please contact Ablynx: Dr Edwin Moses CEO t:   +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e:  edwin.moses@ablynx.com

Marieke Vermeersch Director IR & Corporate Communications t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations FTI Consulting: Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss t: +44 20 3727 1000 e: ablynx@fticonsulting.com

[1] Veyradier, NEJM 2016: "von Willebrand Factor - A new target for TTP treatment?"

[2] Scully et al , Br J Hem 2012; Sarode et al, J Clin Apher 2014; Chaturvedi et al, Am J Hem 2013

[3] Benhamou, Y. et al ., Haematologica 2012

[4] Defined as: 'failure of platelet response after 7 days despite daily plasma exchange treatment' or 'absence of platelet count doubling after 4 days of standard treatment, and LDH>upper limit of normal

[5] Benhamou, Y. et al , Journal of thrombosis and haemostasis 2015

[6] Peyvandi et al , notes to editor NEJM 2016

[7] Press release June 2014 ; Manuscript in the NEJM, Feb 2016; presentation at EHA 2016

[8] Deford et al , Blood 2013

[9] Thejeel et al , American journal of hematology 2016

[10] Kremer Hovinga et al , Blood 2010

[11] Falter et al , Hamostaseologie 2013

pdf format of the press release http://hugin.info/137912/R/2045290/763966.pdf

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading

Top 5 Most Recently Viewed Articles

BearingPoint and Swish AI Join Forces to Elevate ITSM Solutions

Updated Category News Views 119

Transforming IT Service Management with AI As digital transformation accelerates, IT service teams encounter challenges like never before. To tackle these issues, management and technology consultancy BearingPoint has formed a significant partnership with Swish AI, a frontrunner in AI-driven IT Service Management (ITSM) solutions. Together, they aim to greatly improve...

Continue Reading
UAB Kvartalas Closes Subscription Early for Latest Bonds

Updated Category News Views 168

UAB Kvartalas Closes Subscription for 4th Tranche of Bonds UAB "Kvartalas", a legal entity committed to facilitating growth and innovation, has made a significant announcement regarding its bond issuance process. The company, registered with the legal code 305475438, has its headquarters situated at Jogailos St. 4, Vilnius, Republic of Lithuania. In response to...

Continue Reading
Transforming 620 Avenue of the Americas: A New Beginning

Updated Category News Views 97

RXR and Hudson Bay Capital Collaborate on a New Vision The partnership between RXR and Hudson Bay Capital marks an exciting chapter for 620 Avenue of the Americas, a renowned 500,000 square-foot property in the heart of the city. This iconic building is often viewed as a significant piece of real estate, known for its high ceilings and spacious floor plates, becoming a...

Continue Reading
Carolyn Mungo Takes Leadership Role at WFAA and KFAA

Updated Category News Views 230

Carolyn Mungo Takes Leadership Role at WFAA and KFAA TEGNA Inc. (NYSE: TGNA) has exciting news as Carolyn Mungo steps into the role of president and general manager at WFAA, the company’s ABC affiliate, along with KFAA, both serving the vibrant Dallas-Fort Worth area. This transition is effective immediately, marking a new chapter in Mungo's impressive career. A Proven...

Continue Reading
GeoPark Initiates Cash Tender Offer for Senior Notes Redemption

Updated Category News Views 157

GeoPark Starts Cash Tender Offer for Senior Notes GeoPark Limited, a prominent player in the oil and gas sector, has announced that it is launching a cash tender offer for all of its outstanding 5.500% Senior Notes due 2027. This strategic move is designed to improve the company’s capital structure and align its financial resources more effectively. The offering...

Continue Reading